Characteristic | Odds ratio | 95 % Confidence interval |
---|---|---|
Age (yr) | 1.01 | 0.99–1.04 |
Body mass index | 1.01 | 0.97 – 1.05 |
Gender (male vs. female) | 1.59 | 0.77–3.19 |
Ambulatory Status (ambulatory vs. non-ambulatory) | 0.67 | 0.32 – 1.40 |
Alcohol use | 1.28 | 0.61–2.66 |
Surgery | 0.38 | 0.09–1.62 |
Coronary artery disease | 1.13 | 0.50–2.59 |
Chemotherapy | 0.68 | 0.20–2.29 |
Lung Disease | 1.60 | 0.63–4.04 |
Hypertension | 0.82 | 0.40–1.66 |
Immunosuppression | 0.66 | 0.31–1.42 |
Malnutrition | 4.62 | 2.21–9.68 |
Cancer | 0.83 | 0.37–1.82 |
Peripheral vascular disease | 1.34 | 0.39–4.61 |
Renal Failure | 1.92 | 0.90–4.09 |
Steroids | 0.68 | 0.31–1.50 |
Abdominal drain | 0.68 | 0.09–5.26 |
Non-insulin dependent diabetes | 1.24 | 0.42–3.68 |
Insulin-dependent diabetes | 1.19 | 0.52–2.72 |
Foley Catheter | 1.95 | 0.93–4.10 |
Hemodialysis | 1.72 | 0.49 – 6.02 |
Neutropenia | 1.07 | 0.14 – 8.42 |
Open wound | 1.73 | 0.80–3.76 |
Surgical wound | 1.23 | 0.49 – 3.09 |
Transplant | 0.47 | 0.16–1.37 |
Vascular catheter | 0.90 | 0.20 – 3.97 |
Vent support | 1.68 | 0.37–7.59 |
History of Candida | 1.43 | 0.53–3.86 |
History of MRSAӨ | 7.03 | 2.82 – 17.52 |
History of VREӨ | 2.02 | 0.24 – 16.91 |
History of GNӨ | 1.57 | 0.53–4.72 |
Days in hospital in 2 years. prior to admit† (days) | 1.00 | 1.00–1.00 |
Days in ICU in 2 years. prior to admit† (days) | 1.07 | 1.03–1.12 |
Aminoglycosidesa | 1.41 | 0.17–11.31 |
Carbapenemsa | 14.74 | 2.01–108.22 |
1st Gen Cephalosporinsa | 1.11 | 0.32–3.80 |
3rd Gen Cephalosporinsa | 2.65 | 0.95–7.37 |
4th Gen Caphalosporinsa | 1.27 | 0.16 – 10.17 |
Glycopeptides | 2.86 | 1.02 – 7.99 |
Lincosamidesa | 0.62 | 0.08–4.75 |
Macrolidesa | 3.24 | 1.15–9.13 |
Penicillinsa | 2.74 | 0.89–8.48 |
Penicillin Combinationsa | 1.40 | 0.52–3.78 |
Fluoroquinolonesa | 1.76 | 0.81–3.82 |
Sulfonamidesa | 0.20 | 0.03–1.52 |
Drugs against mycobacteriaa | 9.81 | 1.58 – 60.88 |
Other antibioticsb | 4.94 | 1.69–14.48 |